A murine model for non-alcoholic steatohepatitis showing evidence of association between diabetes and hepatocellular carcinoma

[1]  R. Dhanasekaran,et al.  Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics , 2012, Hepatic medicine : evidence and research.

[2]  J. Ertle,et al.  Non‐alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis , 2011, International journal of cancer.

[3]  M. Nagata,et al.  Analysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium , 2011, Pathology international.

[4]  D. V. van Thiel,et al.  Non-Viral Causes of Hepatocellular Carcinoma , 2010, Journal of gastrointestinal cancer.

[5]  J. Ertle,et al.  Nonalcoholic Fatty Liver Disease progresses to HCC in the absence of apparent Cirrhosis , 2011 .

[6]  H. El‐Serag,et al.  The changing pattern of epidemiology in hepatocellular carcinoma. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[7]  Rocio Lopez,et al.  The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.

[8]  S. Harrison,et al.  Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection , 2010, Hepatology.

[9]  C. Tinelli,et al.  Glutamine Synthetase Immunostaining Correlates with Pathologic Features of Hepatocellular Carcinoma and Better Survival after Radiofrequency Thermal Ablation , 2010, Clinical Cancer Research.

[10]  Sheng-Nan Lu,et al.  Neither Diabetes Mellitus nor Overweight Is a Risk Factor for Hepatocellular Carcinoma in a Dual HBV and HCV Endemic Area: Community Cross-Sectional and Case–Control Studies , 2010, The American Journal of Gastroenterology.

[11]  J. Davila.  Editorial: Diabetes and Hepatocellular Carcinoma: What Role Does Diabetes Have in the Presence of Other Known Risk Factors? , 2010, The American Journal of Gastroenterology.

[12]  Zhongjie Sun,et al.  Current views on type 2 diabetes. , 2010, Journal of Endocrinology.

[13]  D. Milewicz,et al.  An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. , 2009, The Journal of clinical investigation.

[14]  M. V. von Herrath,et al.  Mouse Models for Type 1 Diabetes. , 2009, Drug discovery today. Disease models.

[15]  Shankar Subramaniam,et al.  Diet‐induced hepatocellular carcinoma in genetically‐predisposed mice , 2009, Human molecular genetics.

[16]  N. Kawada,et al.  Expression of perilipin and adipophilin in nonalcoholic fatty liver disease; relevance to oxidative injury and hepatocyte ballooning. , 2009, Journal of atherosclerosis and thrombosis.

[17]  I. B. Borel Rinkes,et al.  Mouse models in liver cancer research: a review of current literature. , 2008, World journal of gastroenterology.

[18]  M. Yeh,et al.  Animal models of NASH: Getting both pathology and metabolic context right , 2008, Journal of gastroenterology and hepatology.

[19]  H. Yoshiji,et al.  Decreased phagocytic activity of Kupffer cells in a rat nonalcoholic steatohepatitis model. , 2008, World journal of gastroenterology.

[20]  M. Honda,et al.  Increased oxidative stress precedes the onset of high-fat diet-induced insulin resistance and obesity. , 2008, Metabolism: clinical and experimental.

[21]  F. Trevisani,et al.  Recent advances in the natural history of hepatocellular carcinoma. , 2008, Carcinogenesis.

[22]  J. Girard,et al.  Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. , 2008, The Journal of clinical investigation.

[23]  E. Fisher,et al.  Rapid regression of atherosclerosis: insights from the clinical and experimental literature , 2008, Nature Clinical Practice Cardiovascular Medicine.

[24]  Z. Younossi,et al.  Evaluation and management of obesity-related nonalcoholic fatty liver disease , 2007, Nature Clinical Practice Gastroenterology &Hepatology.

[25]  Michael Karin,et al.  References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production , 2022 .

[26]  J. Iredale.  Models of liver fibrosis: exploring the dynamic nature of inflammation and repair in a solid organ. , 2007, The Journal of clinical investigation.

[27]  S. Gordon.  Macrophage heterogeneity and tissue lipids. , 2007, The Journal of clinical investigation.

[28]  T. Arakawa,et al.  Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: Impact on disease progression , 2006, Hepatology.

[29]  R. Goldin,et al.  Mouse models in non‐alcoholic fatty liver disease and steatohepatitis research , 2006, International journal of experimental pathology.

[30]  K. Lindor,et al.  Nonalcoholic fatty liver disease , 2005, Canadian Medical Association Journal.

[31]  O. Cummings,et al.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.

[32]  Christopher J. Rhodes,et al.  Type 2 Diabetes-a Matter of ß-Cell Life and Death? , 2005, Science.

[33]  C. Rhodes.  Type 2 diabetes-a matter of beta-cell life and death? , 2005, Science.

[34]  R. Green,et al.  Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. , 2004, American journal of physiology. Gastrointestinal and liver physiology.

[35]  T. Mak,et al.  Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. , 2004, The Journal of clinical investigation.

[36]  Wen Shi,et al.  Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. , 2003, Gastroenterology.

[37]  Z. Bloomgarden,et al.  Inflammation and insulin resistance. , 2003, Diabetes care.

[38]  Mauro Salizzoni,et al.  Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. , 2002, Gastroenterology.

[39]  Jan Kitajewski,et al.  New targets of β-catenin signaling in the liver are involved in the glutamine metabolism , 2002, Oncogene.

[40]  K. Matsushima,et al.  Regulation by Chemokines of Circulating Dendritic Cell Precursors, and the Formation of Portal Tract–Associated Lymphoid Tissue, in a Granulomatous Liver Disease , 2001, The Journal of experimental medicine.

[41]  K. Matsushima,et al.  Pivotal role of TARC, a CC chemokine, in bacteria-induced fulminant hepatic failure in mice. , 1998, The Journal of clinical investigation.

[42]  Y. Ogawa,et al.  Tamoxifen-induced fatty liver in patients with breast cancer , 1998, The Lancet.

[43]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.

[44]  P. Scheuer,et al.  The morphology of alcoholic liver disease. , 1982, British medical bulletin.